CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 22 enrolled
Drug / intervention
Osimertinib +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03831932
NCT03831932Phase 2Active
CompareCT.gov

A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Feb 6, 2019·Updated May 28, 2026

In Brief

A Phase 2 clinical trial evaluating Biospecimen Collection, Computed Tomography, and 5 other interventions for Advanced Lung Non-Small Cell Carcinoma and 2 related conditions. Active but no longer recruiting, targeting 22 participants across 11 sites.

Detailed Summary

This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
201920202021202220232024202520262027
First PostedFeb 6, 2019
Enrollment StartMar 16, 2020
Primary CompletionJun 12, 2024
Study CompletionMar 13, 2027
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.4 years ago

Interventions

Biospecimen Collectionprocedure

Undergo blood sample collection

Computed Tomographyprocedure

Undergo CT scan

Magnetic Resonance Elastographyprocedure

Undergo MRI

Osimertinibdrug

Given PO

Positron Emission Tomographyprocedure

Undergo PET scan

Telaglenastat Hydrochloridedrug

Given PO

X-Ray Imagingprocedure

Undergo x-ray imaging